Loading…
Expanding the Availability of Medicare Data Act
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
61pct
22d open
vs 6,526 other HR bills in the 114th — cohort avg 56d
Expanding the Availability of Medicare Data Act Expands the kinds of uses of Medicare data available to qualified entities for quality and patient care improvement activities. (A "qualified entity" is a public or private entity that: [1] is qualified to use claims data to evaluate the performance of service providers and suppliers on measures of quality, efficiency, effectiveness, and resource use; and [2] agrees to meet specified requirements, such as ensuring data security.) Authorizes a qualified entity to use claims data combined with non-claims data the entity has received, as well as information derived from evaluation of service provider and supplier performance, to conduct additional non-public analyses and provide or sell them to authorized users for non-public use (including to assist service providers and suppliers to develop and participate in quality and patient care improvement activities, including new models of care). Defines "authorized users" as service providers, suppliers, employers, health insurance issuers, medical societies or hospital associations, or any other entities approved by the Secretary of Health and Human Services. Prohibits a qualified entity from charging a fee to provide Medicare claims data. Requires a qualified entity and an authorized user to enter into a data use agreement, and prohibits the use of data or analyses for marketing purposes or, except in certain circumstances, its redisclosure. Directs the Secretary to provide Medicare data to qualified clinical data registries for purposes of linking it with clinical outcomes data and performing risk-adjusted, scientifically valid analyses and research to support quality improvement or patient safety. Requires charging a fee to a registry for such data. Amends title XVIII (Medicare) of the Social Security Act (SSAct) to include among standardized extracts of Medicare claims data that may be made available to qualified entities, if the Secretary determines appropriate, also claims data under SSAct titles XIX (Medicaid) and XXI (State Children's Health Insurance) (CHIP). Requires any fees charged for making standardized extracts available to qualified entities to be deposited into the Centers for Medicare & Medicaid Services Program Management Account (currently, into the Federal Supplementary Medical Insurance Trust Fund).
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (5)
2016 · fourth_quarter · Medicare/Medicaid
Referred to the Subcommittee on Health.
Referred to the Subcommittee on Health.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Congress.gov source codes: H11100, H11100-A
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, implementation of the prescriber registration rules and definition of negotiated price. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, e-prescribing, PBM disclosure requirements, specialty pharmacy, mail-service pharmacy, formulary transparency, and medical loss ratio). Regulatory and proposed legislative changes to Medicare part D including non-interference, pharmacy networks, classes of clinical concern, mail-service pharmacy, EGWP waivers, MTM expansion, long term care pharmacy, recovery audit contractors. Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs. Issues related to prescription drug abuse in Medicare. H.R.2: Medicare Access and CHIP Reauthorization Act of 2015 - provisions related to the expansion of availability of Medicare data H.R.244: The MAC Transparency Act H.R.793/S1190: The Ensuring Seniors Access to Local Pharmacies Act H.R. 1021: The Protecting the Integrity of Medicare Act H.R. 1600: The Patient Access to Treatments Act H.R. 804: The Access to Medicare Data Act H.R. 2298: The Medicare Drug Abuse Prevention Act H.R. 953/S.524: The Comprehensive Addiction and Recovery Act - Provisions related to the establishment of a Medicare patient review and restriction lock-in program to prevent prescription opioid abuse. H.R. 2646: The Helping Families in Crisis Act - Provisions related to prescription drug coverage S.2680: Mental Health Reform Act - Provisions related to prescription drug coverage H.R.6: 21st Century Cures H.R.4062: Protecting Seniors Access to Proper Care Act H.R.5951/S.3308: Improving Transparency and Accuracy in Medicare Part D Spending Act
Client expense: $755,506 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), General Services Administration (GSA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE
2016 · fourth_quarter · Health Issues
Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, implementation of the prescriber registration rules and definition of negotiated price. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, e-prescribing, PBM disclosure requirements, specialty pharmacy, mail-service pharmacy, formulary transparency, and medical loss ratio). Regulatory and proposed legislative changes to Medicare part D including non-interference, pharmacy networks, classes of clinical concern, mail-service pharmacy, EGWP waivers, MTM expansion, long term care pharmacy, recovery audit contractors. Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs. Issues related to prescription drug abuse in Medicare. H.R.2: Medicare Access and CHIP Reauthorization Act of 2015 - provisions related to the expansion of availability of Medicare data H.R.244: The MAC Transparency Act H.R.793/S1190: The Ensuring Seniors Access to Local Pharmacies Act H.R.1021: The Protecting the Integrity of Medicare Act H.R.1600: The Patient Access to Treatments Act Provisions related to the 21st Century Cures Initiative (Energy and Commerce) and Innovations for Healthier Americans (HELP Committee). Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, FDA user fees, manufacturer market and data exclusivity, REMS, biosimilars. H.R.804: The Access to Medicare Data Act H.R.2298: The Medicare Drug Abuse Prevention Act H.R.6: 21st Century Cures Act S.2700: The FDA and NIH Workforce Authorization Modernization Act - Provisions related to biologic drugs H.R.2841: The FAST Generics Act S.3056: The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2016 H.R. 4784/S.2651: The Increasing Competition in Pharmaceuticals Act H.R. 5573/S.3094 The Price Relief, Innovation, and Competition for Essential Drugs Act or the PRICED Act
Client expense: $755,506 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), General Services Administration (GSA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE
2016 · fourth_quarter · Pharmacy
Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, implementation of the prescriber registration rules and definition of negotiated price. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, e-prescribing, PBM disclosure requirements, specialty pharmacy, mail-service pharmacy, formulary transparency, and medical loss ratio). Regulatory and proposed legislative changes to Medicare part D including non-interference, pharmacy networks, classes of clinical concern, mail-service pharmacy, EGWP waivers, MTM expansion, long term care pharmacy, recovery audit contractors. Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs. Issues related to prescription drug abuse in Medicare. H.R.2: Medicare Access and CHIP Reauthorization Act of 2015 - provisions related to the expansion of availability of Medicare data H.R.244: The MAC Transparency Act H.R.793S1190: The Ensuring Seniors Access to Local Pharmacies Act H.R.1021: The Protecting the Integrity of Medicare Act H.R.1600: The Patient Access to Treatments Act H.R.804: The Access to Medicare Data Act H.R.2298: The Medicare Drug Abuse Prevention Act H.R.6: 21st Century Cures Act H.R. 1735/S.1376: The National Defense Authorization Act - Provisions related to TRICARE pharmacy H.R. 4062: Protecting Seniors Access to Proper Care Act H.R. 5951/ S.3308: Improving Transparency and Accuracy in Medicare Part D Spending Act
Client expense: $755,506 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), General Services Administration (GSA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE
2016 · fourth_quarter · Medicare/Medicaid
Medicare; Medicaid; Pharmacy Payments; Average Manufacturer Pricing; Prescription Drug Reimburesement; Direct Negotiation; Medicare Drug Rebate; Medicare Part D Coverage; and HR 804, Expanding the Availability of Medicare Data Act
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Medicare/Medicaid
Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, implementation of the prescriber registration rules and definition of negotiated price. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, e-prescribing, PBM disclosure requirements, specialty pharmacy, mail-service pharmacy, formulary transparency, and medical loss ratio). Regulatory and proposed legislative changes to Medicare part D including non-interference, pharmacy networks, classes of clinical concern, mail-service pharmacy, EGWP waivers, MTM expansion, long term care pharmacy, recovery audit contractors. Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs. Issues related to prescription drug abuse in Medicare. H.R.2: Medicare Access and CHIP Reauthorization Act of 2015 - provisions related to the expansion of availability of Medicare data H.R.244: The MAC Transparency Act H.R.793/S1190: The Ensuring Seniors Access to Local Pharmacies Act H.R. 1021: The Protecting the Integrity of Medicare Act H.R. 1600: The Patient Access to Treatments Act H.R. 804: The Access to Medicare Data Act H.R. 2298: The Medicare Drug Abuse Prevention Act H.R. 953/S.524: The Comprehensive Addiction and Recovery Act - Provisions related to the establishment of a Medicare patient review and restriction lock-in program to prevent prescription opioid abuse. H.R. 2646: The Helping Families in Crisis Act - Provisions related to prescription drug coverage S.2680: Mental Health Reform Act - Provisions related to prescription drug coverage H.R.6: 21st Century Cures H.R.4062: Protecting Seniors Access to Proper Care Act H.R.5951/S.3308: Improving Transparency and Accuracy in Medicare Part D Spending Act
Client expense: $643,584 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), General Services Administration (GSA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE
2016 · third_quarter · Pharmacy
Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, implementation of the prescriber registration rules and definition of negotiated price. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, e-prescribing, PBM disclosure requirements, specialty pharmacy, mail-service pharmacy, formulary transparency, and medical loss ratio). Regulatory and proposed legislative changes to Medicare part D including non-interference, pharmacy networks, classes of clinical concern, mail-service pharmacy, EGWP waivers, MTM expansion, long term care pharmacy, recovery audit contractors. Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs. Issues related to prescription drug abuse in Medicare. H.R.2: Medicare Access and CHIP Reauthorization Act of 2015 - provisions related to the expansion of availability of Medicare data H.R.244: The MAC Transparency Act H.R.793S1190: The Ensuring Seniors Access to Local Pharmacies Act H.R.1021: The Protecting the Integrity of Medicare Act H.R.1600: The Patient Access to Treatments Act H.R.804: The Access to Medicare Data Act H.R.2298: The Medicare Drug Abuse Prevention Act H.R.6: 21st Century Cures Act H.R. 1735/S.1376: The National Defense Authorization Act - Provisions related to TRICARE pharmacy H.R. 4062: Protecting Seniors Access to Proper Care Act H.R. 5951/ S.3308: Improving Transparency and Accuracy in Medicare Part D Spending Act
Client expense: $643,584 · Firm income: Not reported
2016 · third_quarter · Health Issues
Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, implementation of the prescriber registration rules and definition of negotiated price. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, e-prescribing, PBM disclosure requirements, specialty pharmacy, mail-service pharmacy, formulary transparency, and medical loss ratio). Regulatory and proposed legislative changes to Medicare part D including non-interference, pharmacy networks, classes of clinical concern, mail-service pharmacy, EGWP waivers, MTM expansion, long term care pharmacy, recovery audit contractors. Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs. Issues related to prescription drug abuse in Medicare. H.R.2: Medicare Access and CHIP Reauthorization Act of 2015 - provisions related to the expansion of availability of Medicare data H.R.244: The MAC Transparency Act H.R.793/S1190: The Ensuring Seniors Access to Local Pharmacies Act H.R.1021: The Protecting the Integrity of Medicare Act H.R.1600: The Patient Access to Treatments Act Provisions related to the 21st Century Cures Initiative (Energy and Commerce) and Innovations for Healthier Americans (HELP Committee). Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, FDA user fees, manufacturer market and data exclusivity, REMS, biosimilars. H.R.804: The Access to Medicare Data Act H.R.2298: The Medicare Drug Abuse Prevention Act H.R.6: 21st Century Cures Act S.2700: The FDA and NIH Workforce Authorization Modernization Act - Provisions related to biologic drugs H.R.2841: The FAST Generics Act S.3056: The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2016 H.R. 4784/S.2651: The Increasing Competition in Pharmaceuticals Act H.R. 5573/S.3094 The Price Relief, Innovation, and Competition for Essential Drugs Act or the PRICED Act
2016 · third_quarter · Medicare/Medicaid
Medicare; Medicaid; Pharmacy Payments; Average Manufacturer Pricing; Prescription Drug Reimburesement; Direct Negotiation; Medicare Drug Rebate; Medicare Part D Coverage; and HR 804, Expanding the Availability of Medicare Data Act
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · second_quarter · Health Issues
Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, implementation of the prescriber registration rules and definition of negotiated price. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, e-prescribing, PBM disclosure requirements, specialty pharmacy, mail-service pharmacy, formulary transparency, and medical loss ratio). Regulatory and proposed legislative changes to Medicare part D including non-interference, pharmacy networks, classes of clinical concern, mail-service pharmacy, EGWP waivers, MTM expansion, long term care pharmacy, recovery audit contractors. Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs. Issues related to prescription drug abuse in Medicare. H.R.2: Medicare Access and CHIP Reauthorization Act of 2015 - provisions related to the expansion of availability of Medicare data H.R.244: The MAC Transparency Act H.R.793/S1190: The Ensuring Seniors Access to Local Pharmacies Act H.R.1021: The Protecting the Integrity of Medicare Act H.R.1600: The Patient Access to Treatments Act Provisions related to the 21st Century Cures Initiative (Energy and Commerce) and Innovations for Healthier Americans (HELP Committee). Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, FDA user fees, manufacturer market and data exclusivity, REMS, biosimilars. H.R.804: The Access to Medicare Data Act H.R.2298: The Medicare Drug Abuse Prevention Act H.R.6: 21st Century Cures Act S.2700: The FDA and NIH Workforce Authorization Modernization Act - Provisions related to biologic drugs H.R.2841: The FAST Generics Act S.3056: The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2016 H.R. 4784/S.2651: The Increasing Competition in Pharmaceuticals Act H.R. 5573/S.3094 The Price Relief, Innovation, and Competition for Essential Drugs Act or the PRICED Act
2016 · second_quarter · Medicare/Medicaid
Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, implementation of the prescriber registration rules and definition of negotiated price. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, e-prescribing, PBM disclosure requirements, specialty pharmacy, mail-service pharmacy, formulary transparency, and medical loss ratio). Regulatory and proposed legislative changes to Medicare part D including non-interference, pharmacy networks, classes of clinical concern, mail-service pharmacy, EGWP waivers, MTM expansion, long term care pharmacy, recovery audit contractors. Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs. Issues related to prescription drug abuse in Medicare. H.R.2: Medicare Access and CHIP Reauthorization Act of 2015 - provisions related to the expansion of availability of Medicare data H.R.244: The MAC Transparency Act H.R.793/S1190: The Ensuring Seniors Access to Local Pharmacies Act H.R. 1021: The Protecting the Integrity of Medicare Act H.R. 1600: The Patient Access to Treatments Act H.R. 804: The Access to Medicare Data Act H.R. 2298: The Medicare Drug Abuse Prevention Act HR953/S524: The Comprehensive Addiction and Recovery Act - Provisions related to the establishment of a Medicare patient review and restriction lock-in program to prevent prescription opioid abuse. H.R. 2646: The Helping Families in Crisis Act - Provisions related to prescription drug coverage S.2680: Mental Health Reform Act - Provisions related to prescription drug coverage H.R.6: 21st Century Cures
2016 · second_quarter · Pharmacy
Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, implementation of the prescriber registration rules and definition of negotiated price. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, e-prescribing, PBM disclosure requirements, specialty pharmacy, mail-service pharmacy, formulary transparency, and medical loss ratio). Regulatory and proposed legislative changes to Medicare part D including non-interference, pharmacy networks, classes of clinical concern, mail-service pharmacy, EGWP waivers, MTM expansion, long term care pharmacy, recovery audit contractors. Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs. Issues related to prescription drug abuse in Medicare. H.R.2: Medicare Access and CHIP Reauthorization Act of 2015 - provisions related to the expansion of availability of Medicare data H.R.244: The MAC Transparency Act H.R.793S1190: The Ensuring Seniors Access to Local Pharmacies Act H.R.1021: The Protecting the Integrity of Medicare Act H.R.1600: The Patient Access to Treatments Act H.R.804: The Access to Medicare Data Act H.R.2298: The Medicare Drug Abuse Prevention Act H.R.6: 21st Century Cures Act H.R. 1735/S.1376: The National Defense Authorization Act - Provisions related to TRICARE pharmacy
Client expense: $632,600 · Firm income: Not reported
2016 · second_quarter · Medicare/Medicaid
Medicare; Medicaid; Pharmacy Payments; Average Manufacturer Pricing; Prescription Drug Reimburesement; Direct Negotiation; Medicare Drug Rebate; Medicare Part D Coverage; and HR 804, Expanding the Availability of Medicare Data Act
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · first_quarter · Pharmacy
Issues related to PBM's - no specific legislation Issues related to preferred pharmacy networks, mail order and incentives Issues related to prescription drug abuse, pharmacist provider status, drug pricing and drug supply chain safety. H.R.1600 - A bill to amend title XXVII of the Public Health Service Act to limit co-payment, coinsurance, or other cost-sharing requirements applicable to prescription drugs in a specialty drug tier to the dollar amount (or its equivalent) of such requirements applicable to prescription drugs in a non-preferred brand drug tier, and for other purposes. H.R.804 - Expanding the Availability of Medicare Data Act H.R.592 - Pharmacy and Medically Underserved Areas Enhancement Act S.314 - Pharmacy and Medically Underserved Areas Enhancement Act H.R.244 - MAC Transparency Act H.R.1021 - Protecting the Integrity of Medicare Act of 2015 S.776 - Medication Therapy Management Empowerment Act of 2015 H.R.471 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015 S.483 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015 Issues related to anti-PBM issues
Client expense: Not reported · Firm income: $60,000
2016 · first_quarter · Medicare/Medicaid
Medicare; Medicaid; Pharmacy Payments; Average Manufacturer Pricing; Prescription Drug Reimburesement; Direct Negotiation; Medicare Drug Rebate; Medicare Part D Coverage; and HR 804, Expanding the Availability of Medicare Data Act
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · first_quarter · Pharmacy
Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, implementation of the prescriber registration rules and definition of negotiated price. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, e-prescribing, PBM disclosure requirements, specialty pharmacy, mail-service pharmacy, formulary transparency, and medical loss ratio). Regulatory and proposed legislative changes to Medicare part D including non-interference, pharmacy networks, classes of clinical concern, mail-service pharmacy, EGWP waivers, MTM expansion, long term care pharmacy, recovery audit contractors. Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs. Issues related to prescription drug abuse in Medicare. H.R.2 Medicare Access and CHIP Reauthorization Act of 2015 - provisions related to the expansion of availability of Medicare data H.R.244, The MAC Transparency Act H.R.793S1190, The Ensuring Seniors Access to Local Pharmacies Act H.R. 1021, The Protecting the Integrity of Medicare Act H.R.1600, The Patient Access to Treatments Act H.R. 804, The Access to Medicare Data Act H.R. 2298, The Medicare Drug Abuse Prevention Act H.R. 6, Century Cures Act
Client expense: $696,470 · Firm income: Not reported
2016 · first_quarter · Medicare/Medicaid
Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, implementation of the prescriber registration rules and definition of negotiated price. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, e-prescribing, PBM disclosure requirements, specialty pharmacy, mail-service pharmacy, formulary transparency, and medical loss ratio). Regulatory and proposed legislative changes to Medicare part D including non-interference, pharmacy networks, classes of clinical concern, mail-service pharmacy, EGWP waivers, MTM expansion, long term care pharmacy, recovery audit contractors. Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs. Issues related to prescription drug abuse in Medicare. H.R.2 Medicare Access and CHIP Reauthorization Act of 2015 - provisions related to the expansion of availability of Medicare data H.R.244, The MAC Transparency Act H.R.793/S1190, The Ensuring Seniors Access to Local Pharmacies Act H.R. 1021, The Protecting the Integrity of Medicare Act H.R.1600, The Patient Access to Treatments Act H.R. 804, The Access to Medicare Data Act H.R. 2298, The Medicare Drug Abuse Prevention Act H.R. 6, Century Cures Act
Client expense: $696,470 · Firm income: Not reported
2016 · first_quarter · Health Issues
Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, implementation of the prescriber registration rules and definition of negotiated price. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, e-prescribing, PBM disclosure requirements, specialty pharmacy, mail-service pharmacy, formulary transparency, and medical loss ratio). Regulatory and proposed legislative changes to Medicare part D including non-interference, pharmacy networks, classes of clinical concern, mail-service pharmacy, EGWP waivers, MTM expansion, long term care pharmacy, recovery audit contractors. Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs. Issues related to prescription drug abuse in Medicare. H.R.2 Medicare Access and CHIP Reauthorization Act of 2015 - provisions related to the expansion of availability of Medicare data H.R.244, The MAC Transparency Act H.R.793/S1190, The Ensuring Seniors Access to Local Pharmacies Act H.R. 1021, The Protecting the Integrity of Medicare Act H.R.1600, The Patient Access to Treatments Act Provisions related to the 21st Century Cures Initiative (Energy and Commerce) and Innovations for Healthier Americans (HELP Committee). Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, FDA user fees, manufacturer market and data exclusivity, REMS, biosimilars. H.R. 804, The Access to Medicare Data Act H.R. 2298, The Medicare Drug Abuse Prevention Act H.R. 6, Century Cures Act
Client expense: $696,470 · Firm income: Not reported
2015 · fourth_quarter · Pharmacy
Issues related to PBM's - no specific legislation Issues related to preferred pharmacy networks, mail order and incentives Issues related to prescription drug abuse, pharmacist provider status, drug pricing and drug supply chain safety. H.R.1600 - A bill to amend title XXVII of the Public Health Service Act to limit co-payment, coinsurance, or other cost-sharing requirements applicable to prescription drugs in a specialty drug tier to the dollar amount (or its equivalent) of such requirements applicable to prescription drugs in a non-preferred brand drug tier, and for other purposes. H.R.804 - Expanding the Availability of Medicare Data Act H.R.592 - Pharmacy and Medically Underserved Areas Enhancement Act S.314 - Pharmacy and Medically Underserved Areas Enhancement Act H.R.244 - MAC Transparency Act H.R.1021 - Protecting the Integrity of Medicare Act of 2015 S.776 - Medication Therapy Management Empowerment Act of 2015 H.R.471 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015 S.483 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015 Issues related to anti-PBM issues
Client expense: Not reported · Firm income: $60,000
2015 · fourth_quarter · Pharmacy
Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, implementation of the prescriber registration rules and definition of negotiated price. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, e-prescribing, PBM disclosure requirements, specialty pharmacy, mail-service pharmacy, formulary transparency, and medical loss ratio). Regulatory and proposed legislative changes to Medicare part D including non-interference, pharmacy networks, classes of clinical concern, mail-service pharmacy, EGWP waivers, MTM expansion, long term care pharmacy, recovery audit contractors. Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs. Issues related to prescription drug abuse in Medicare. H.R.2 Medicare Access and CHIP Reauthorization Act of 2015 - provisions related to the expansion of availability of Medicare data H.R.244, The MAC Transparency Act H.R.793S1190, The Ensuring Seniors Access to Local Pharmacies Act H.R. 1021, The Protecting the Integrity of Medicare Act H.R.1600, The Patient Access to Treatments Act H.R. 804, The Access to Medicare Data Act H.R. 2298, The Medicare Drug Abuse Prevention Act H.R. 6, Century Cures Act
Client expense: $619,255 · Firm income: Not reported
2015 · fourth_quarter · Health Issues
Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, implementation of the prescriber registration rules and definition of negotiated price. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, e-prescribing, PBM disclosure requirements, specialty pharmacy, mail-service pharmacy, formulary transparency, and medical loss ratio). Regulatory and proposed legislative changes to Medicare part D including non-interference, pharmacy networks, classes of clinical concern, mail-service pharmacy, EGWP waivers, MTM expansion, long term care pharmacy, recovery audit contractors. Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs. Issues related to prescription drug abuse in Medicare. H.R.2 Medicare Access and CHIP Reauthorization Act of 2015 - provisions related to the expansion of availability of Medicare data H.R.244, The MAC Transparency Act H.R.793/S1190, The Ensuring Seniors Access to Local Pharmacies Act H.R. 1021, The Protecting the Integrity of Medicare Act H.R.1600, The Patient Access to Treatments Act Provisions related to the 21st Century Cures Initiative (Energy and Commerce) and Innovations for Healthier Americans (HELP Committee). Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, FDA user fees, manufacturer market and data exclusivity, REMS, biosimilars. H.R. 804, The Access to Medicare Data Act H.R. 2298, The Medicare Drug Abuse Prevention Act H.R. 6, Century Cures Act
Client expense: $619,255 · Firm income: Not reported
2015 · fourth_quarter · Medicare/Medicaid
Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, implementation of the prescriber registration rules and definition of negotiated price. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, e-prescribing, PBM disclosure requirements, specialty pharmacy, mail-service pharmacy, formulary transparency, and medical loss ratio). Regulatory and proposed legislative changes to Medicare part D including non-interference, pharmacy networks, classes of clinical concern, mail-service pharmacy, EGWP waivers, MTM expansion, long term care pharmacy, recovery audit contractors. Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs. Issues related to prescription drug abuse in Medicare. H.R.2 Medicare Access and CHIP Reauthorization Act of 2015 - provisions related to the expansion of availability of Medicare data H.R.244, The MAC Transparency Act H.R.793/S1190, The Ensuring Seniors Access to Local Pharmacies Act H.R. 1021, The Protecting the Integrity of Medicare Act H.R.1600, The Patient Access to Treatments Act H.R. 804, The Access to Medicare Data Act H.R. 2298, The Medicare Drug Abuse Prevention Act H.R. 6, Century Cures Act
Client expense: $619,255 · Firm income: Not reported
2015 · fourth_quarter · Medicare/Medicaid
Medicare; Medicaid; Pharmacy Payments; Average Manufacturer Pricing; Prescription Drug Reimburesement; Direct Negotiation; Medicare Drug Rebate; Medicare Part D Coverage; and HR 804, Expanding the Availability of Medicare Data Act
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · third_quarter · Pharmacy
Issues related to prescription drug abuse, preferred pharmacy networks, pharmacist provider status, drug pricing and drug supply chain safety & Tricare. HR 1600 :A bill to amend title XXVII of the Public Health Service Act to limit co-payment, coinsurance, or other cost-sharing requirements applicable to prescription drugs in a specialty drug tier to the dollar amount (or its equivalent) of such requirements applicable to prescription drugs in a non-preferred brand drug tier, and for other purposes. HR 804 - Expanding the Availability of Medicare Data Act HR 592 - Pharmacy and Medically Underserved Areas Enhancement Act S 314 - Pharmacy and Medically Underserved Areas Enhancement Act HR 244 - MAC Transparency Act H.R.1021 - Protecting the Integrity of Medicare Act of 2015 S.776 - Medication Therapy Management Empowerment Act of 2015 H.R.471 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015 S.483 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015 HR 1735-National Defense Authorization Act for Fiscal Year 2016 HR 6-Stopping Medication Abuse and Protecting Seniors Act of 2015 S. 1913-Stopping Medication Abuse and Protecting Seniors Act of 2015 HR 1725-National All Schedules Prescription Electronic Reporting Reauthorization Act of 2015 S 480-National All Schedules Prescription Electronic Reporting Reauthorization Act of 201
Client expense: $3,250,000 · Firm income: Not reported
2015 · third_quarter · Pharmacy
Issues related to PBM's - no specific legislation Issues related to preferred pharmacy networks, mail order and incentives Issues related to prescription drug abuse, pharmacist provider status, drug pricing and drug supply chain safety. H.R.1600 - A bill to amend title XXVII of the Public Health Service Act to limit co-payment, coinsurance, or other cost-sharing requirements applicable to prescription drugs in a specialty drug tier to the dollar amount (or its equivalent) of such requirements applicable to prescription drugs in a non-preferred brand drug tier, and for other purposes. H.R.804 - Expanding the Availability of Medicare Data Act H.R.592 - Pharmacy and Medically Underserved Areas Enhancement Act S.314 - Pharmacy and Medically Underserved Areas Enhancement Act H.R.244 - MAC Transparency Act H.R.1021 - Protecting the Integrity of Medicare Act of 2015 S.776 - Medication Therapy Management Empowerment Act of 2015 H.R.471 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015 S.483 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015
Client expense: Not reported · Firm income: $60,000
2015 · third_quarter · Health Issues
Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, implementation of the prescriber registration rules and definition of negotiated price. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, e-prescribing, PBM disclosure requirements, specialty pharmacy, mail-service pharmacy, formulary transparency, and medical loss ratio). Regulatory and proposed legislative changes to Medicare part D including non-interference, pharmacy networks, classes of clinical concern, mail-service pharmacy, EGWP waivers, MTM expansion, long term care pharmacy, recovery audit contractors. Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs. Issues related to prescription drug abuse in Medicare. H.R.2 Medicare Access and CHIP Reauthorization Act of 2015 - provisions related to the expansion of availability of Medicare data H.R.244, The MAC Transparency Act H.R.793/S1190, The Ensuring Seniors Access to Local Pharmacies Act H.R. 1021, The Protecting the Integrity of Medicare Act H.R.1600, The Patient Access to Treatments Act Provisions related to the 21st Century Cures Initiative (Energy and Commerce) and Innovations for Healthier Americans (HELP Committee). Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, FDA user fees, manufacturer market and data exclusivity, REMS, biosimilars. H.R. 804, The Access to Medicare Data Act H.R. 2298, The Medicare Drug Abuse Prevention Act H.R. 6, Century Cures Act
Client expense: $622,142 · Firm income: Not reported
2015 · third_quarter · Medicare/Medicaid
Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, implementation of the prescriber registration rules and definition of negotiated price. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, e-prescribing, PBM disclosure requirements, specialty pharmacy, mail-service pharmacy, formulary transparency, and medical loss ratio). Regulatory and proposed legislative changes to Medicare part D including non-interference, pharmacy networks, classes of clinical concern, mail-service pharmacy, EGWP waivers, MTM expansion, long term care pharmacy, recovery audit contractors. Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs. Issues related to prescription drug abuse in Medicare. H.R.2 Medicare Access and CHIP Reauthorization Act of 2015 - provisions related to the expansion of availability of Medicare data H.R.244, The MAC Transparency Act H.R.793/S1190, The Ensuring Seniors Access to Local Pharmacies Act H.R. 1021, The Protecting the Integrity of Medicare Act H.R.1600, The Patient Access to Treatments Act H.R. 804, The Access to Medicare Data Act H.R. 2298, The Medicare Drug Abuse Prevention Act H.R. 6, Century Cures Act
Client expense: $622,142 · Firm income: Not reported
2015 · third_quarter · Pharmacy
Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, implementation of the prescriber registration rules and definition of negotiated price. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, e-prescribing, PBM disclosure requirements, specialty pharmacy, mail-service pharmacy, formulary transparency, and medical loss ratio). Regulatory and proposed legislative changes to Medicare part D including non-interference, pharmacy networks, classes of clinical concern, mail-service pharmacy, EGWP waivers, MTM expansion, long term care pharmacy, recovery audit contractors. Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs. Issues related to prescription drug abuse in Medicare. H.R.2 Medicare Access and CHIP Reauthorization Act of 2015 - provisions related to the expansion of availability of Medicare data H.R.244, The MAC Transparency Act H.R.793S1190, The Ensuring Seniors Access to Local Pharmacies Act H.R. 1021, The Protecting the Integrity of Medicare Act H.R.1600, The Patient Access to Treatments Act H.R. 804, The Access to Medicare Data Act H.R. 2298, The Medicare Drug Abuse Prevention Act H.R. 6, Century Cures Act
Client expense: $622,142 · Firm income: Not reported
2015 · third_quarter · Medicare/Medicaid
Medicare; Medicaid; Pharmacy Payments; Average Manufacturer Pricing; Prescription Drug Reimburesement; Direct Negotiation; Medicare Drug Rebate; Medicare Part D Coverage; and HR 804, Expanding the Availability of Medicare Data Act
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · second_quarter · Pharmacy
Issues related to prescription drug abuse, preferred pharmacy networks, pharmacist provider status, drug pricing and drug supply chain safety & Tricare. HR 1600 :A bill to amend title XXVII of the Public Health Service Act to limit co-payment, coinsurance, or other cost-sharing requirements applicable to prescription drugs in a specialty drug tier to the dollar amount (or its equivalent) of such requirements applicable to prescription drugs in a non-preferred brand drug tier, and for other purposes. HR 804 - Expanding the Availability of Medicare Data Act HR 592 - Pharmacy and Medically Underserved Areas Enhancement Act S 314 - Pharmacy and Medically Underserved Areas Enhancement Act HR 244 - MAC Transparency Act H.R.1021 - Protecting the Integrity of Medicare Act of 2015 S.776 - Medication Therapy Management Empowerment Act of 2015 H.R.471 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015 S.483 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015 HR 1735-National Defense Authorization Act for Fiscal Year 2016
Client expense: $3,700,000 · Firm income: Not reported
2015 · second_quarter · Medicare/Medicaid
Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, implementation of the prescriber registration rules and definition of negotiated price. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, e-prescribing, PBM disclosure requirements, specialty pharmacy, mail-service pharmacy, formulary transparency, and medical loss ratio). Regulatory and proposed legislative changes to Medicare part D including non-interference, pharmacy networks, classes of clinical concern, mail-service pharmacy, EGWP waivers, MTM expansion, long term care pharmacy, recovery audit contractors. Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs. Issues related to prescription drug abuse in Medicare. H.R.2 Medicare Access and CHIP Reauthorization Act of 2015 - provisions related to the expansion of availability of Medicare data H.R.244, The MAC Transparency Act H.R.793/S1190, The Ensuring Seniors Access to Local Pharmacies Act H.R. 1021, The Protecting the Integrity of Medicare Act H.R.1600, The Patient Access to Treatments Act H.R. 804, The Access to Medicare Data Act H.R. 2298, The Medicare Drug Abuse Prevention Act H.R. 6, Century Cures Act
Client expense: $622,142 · Firm income: Not reported
2015 · second_quarter · Pharmacy
Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, implementation of the prescriber registration rules and definition of negotiated price. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, e-prescribing, PBM disclosure requirements, specialty pharmacy, mail-service pharmacy, formulary transparency, and medical loss ratio). Regulatory and proposed legislative changes to Medicare part D including non-interference, pharmacy networks, classes of clinical concern, mail-service pharmacy, EGWP waivers, MTM expansion, long term care pharmacy, recovery audit contractors. Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs. Issues related to prescription drug abuse in Medicare. H.R.2 Medicare Access and CHIP Reauthorization Act of 2015 - provisions related to the expansion of availability of Medicare data H.R.244, The MAC Transparency Act H.R.793S1190, The Ensuring Seniors Access to Local Pharmacies Act H.R. 1021, The Protecting the Integrity of Medicare Act H.R.1600, The Patient Access to Treatments Act H.R. 804, The Access to Medicare Data Act H.R. 2298, The Medicare Drug Abuse Prevention Act H.R. 6, Century Cures Act
Client expense: $622,142 · Firm income: Not reported
2015 · second_quarter · Health Issues
Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, implementation of the prescriber registration rules and definition of negotiated price. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, e-prescribing, PBM disclosure requirements, specialty pharmacy, mail-service pharmacy, formulary transparency, and medical loss ratio). Regulatory and proposed legislative changes to Medicare part D including non-interference, pharmacy networks, classes of clinical concern, mail-service pharmacy, EGWP waivers, MTM expansion, long term care pharmacy, recovery audit contractors. Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs. Issues related to prescription drug abuse in Medicare. H.R.2 Medicare Access and CHIP Reauthorization Act of 2015 - provisions related to the expansion of availability of Medicare data H.R.244, The MAC Transparency Act H.R.793/S1190, The Ensuring Seniors Access to Local Pharmacies Act H.R. 1021, The Protecting the Integrity of Medicare Act H.R.1600, The Patient Access to Treatments Act Provisions related to the 21st Century Cures Initiative (Energy and Commerce) and Innovations for Healthier Americans (HELP Committee). Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, FDA user fees, manufacturer market and data exclusivity, REMS, biosimilars. H.R. 804, The Access to Medicare Data Act H.R. 2298, The Medicare Drug Abuse Prevention Act H.R. 6, Century Cures Act
Client expense: $622,142 · Firm income: Not reported
2015 · second_quarter · Pharmacy
Issues related to prescription drug abuse, preferred pharmacy networks, pharmacist provider status, drug pricing and drug supply chain safety & Tricare. HR 1600 :A bill to amend title XXVII of the Public Health Service Act to limit co-payment, coinsurance, or other cost-sharing requirements applicable to prescription drugs in a specialty drug tier to the dollar amount (or its equivalent) of such requirements applicable to prescription drugs in a non-preferred brand drug tier, and for other purposes. HR 804 - Expanding the Availability of Medicare Data Act HR 592 - Pharmacy and Medically Underserved Areas Enhancement Act S 314 - Pharmacy and Medically Underserved Areas Enhancement Act HR 244 - MAC Transparency Act H.R.1021 - Protecting the Integrity of Medicare Act of 2015 S.776 - Medication Therapy Management Empowerment Act of 2015 H.R.471 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015 S.483 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015 HR 1735-National Defense Authorization Act for Fiscal Year 2016
Client expense: $3,600,000 · Firm income: Not reported
2015 · second_quarter · Pharmacy
Issues related to PBM's - no specific legislation Issues related to preferred pharmacy networks, mail order and incentives Issues related to prescription drug abuse, pharmacist provider status, drug pricing and drug supply chain safety. H.R.1600 - A bill to amend title XXVII of the Public Health Service Act to limit co-payment, coinsurance, or other cost-sharing requirements applicable to prescription drugs in a specialty drug tier to the dollar amount (or its equivalent) of such requirements applicable to prescription drugs in a non-preferred brand drug tier, and for other purposes. H.R.804 - Expanding the Availability of Medicare Data Act H.R.592 - Pharmacy and Medically Underserved Areas Enhancement Act S.314 - Pharmacy and Medically Underserved Areas Enhancement Act H.R.244 - MAC Transparency Act H.R.1021 - Protecting the Integrity of Medicare Act of 2015 S.776 - Medication Therapy Management Empowerment Act of 2015 H.R.471 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015 S.483 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015
Client expense: Not reported · Firm income: $60,000
2015 · second_quarter · Medicare/Medicaid
Legislative and regulatory issues that affect the prescription drug benefit or prescription drug affordability, including: HR244 (MAC Pricing); HR471 (Controlled Substances Registration); HR592 (Pharmacy Provider Status); HR69 (ASP Prompt Pay Exclusion); HR793 (Any Willing Pharmacy); HR804 (Access to Medicare Data); HR818 (PRIME Act); HR971 (OPEN Act); HR1021 (PIMA); HR1353 (New Therapeutic Entities); HR1735 (NDAA); HR2175 (FEHBP Transparency); HR2298 (Medicare Rx Abuse Prevention); S31 (Direct Negotiation); S314 (Pharmacy Provider Status); S1083 (Medicare Rebates); S1190 (Any Willing Pharmacy); S1364 (Medicaid Generic Rebates); S1376 (NDAA); S1431(Rx Abuse Prevention & Treatment).
Client expense: Not reported · Firm income: Not reported
2015 · second_quarter · Health Issues
Legislative and regulatory issues that affect the prescription drug benefit or prescription drug affordability, including: HR244 (MAC Pricing); HR471 (Controlled Substances Registration); HR592 (Pharmacy Provider Status); HR69 (ASP Prompt Pay Exclusion); HR793 (Any Willing Pharmacy); HR804 (Access to Medicare Data); HR818 (PRIME Act); HR971 (OPEN Act); HR1021 (PIMA); HR1353 (New Therapeutic Entities); HR1735 (NDAA); HR2175 (FEHBP Transparency); HR2298 (Medicare Rx Abuse Prevention); S31 (Direct Negotiation); S314 (Pharmacy Provider Status); S1083 (Medicare Rebates); S1190 (Any Willing Pharmacy); S1364 (Medicaid Generic Rebates); S1376 (NDAA); S1431(Rx Abuse Prevention & Treatment).
Client expense: Not reported · Firm income: Not reported
2015 · second_quarter · Defense
Legislative and regulatory issues that affect the prescription drug benefit or prescription drug affordability, including: HR244 (MAC Pricing); HR471 (Controlled Substances Registration); HR592 (Pharmacy Provider Status); HR69 (ASP Prompt Pay Exclusion); HR793 (Any Willing Pharmacy); HR804 (Access to Medicare Data); HR818 (PRIME Act); HR971 (OPEN Act); HR1021 (PIMA); HR1353 (New Therapeutic Entities); HR1735 (NDAA); HR2175 (FEHBP Transparency); HR2298 (Medicare Rx Abuse Prevention); S31 (Direct Negotiation); S314 (Pharmacy Provider Status); S1083 (Medicare Rebates); S1190 (Any Willing Pharmacy); S1364 (Medicaid Generic Rebates); S1376 (NDAA); S1431(Rx Abuse Prevention & Treatment).
Client expense: Not reported · Firm income: Not reported
2015 · second_quarter · Labor Issues/Antitrust/Workplace
Legislative and regulatory issues that affect the prescription drug benefit or prescription drug affordability, including: HR244 (MAC Pricing); HR471 (Controlled Substances Registration); HR592 (Pharmacy Provider Status); HR69 (ASP Prompt Pay Exclusion); HR793 (Any Willing Pharmacy); HR804 (Access to Medicare Data); HR818 (PRIME Act); HR971 (OPEN Act); HR1021 (PIMA); HR1353 (New Therapeutic Entities); HR1735 (NDAA); HR2175 (FEHBP Transparency); HR2298 (Medicare Rx Abuse Prevention); S31 (Direct Negotiation); S314 (Pharmacy Provider Status); S1083 (Medicare Rebates); S1190 (Any Willing Pharmacy); S1364 (Medicaid Generic Rebates); S1376 (NDAA); S1431(Rx Abuse Prevention & Treatment).
Client expense: Not reported · Firm income: Not reported
2015 · second_quarter · Pharmacy
Legislative and regulatory issues that affect the prescription drug benefit or prescription drug affordability, including: HR244 (MAC Pricing); HR471 (Controlled Substances Registration); HR592 (Pharmacy Provider Status); HR69 (ASP Prompt Pay Exclusion); HR793 (Any Willing Pharmacy); HR804 (Access to Medicare Data); HR818 (PRIME Act); HR971 (OPEN Act); HR1021 (PIMA); HR1353 (New Therapeutic Entities); HR1735 (NDAA); HR2175 (FEHBP Transparency); HR2298 (Medicare Rx Abuse Prevention); S31 (Direct Negotiation); S314 (Pharmacy Provider Status); S1083 (Medicare Rebates); S1190 (Any Willing Pharmacy); S1364 (Medicaid Generic Rebates); S1376 (NDAA); S1431(Rx Abuse Prevention & Treatment).
Client expense: Not reported · Firm income: Not reported
2015 · second_quarter · Postal
Legislative and regulatory issues that affect the prescription drug benefit or prescription drug affordability, including: HR244 (MAC Pricing); HR471 (Controlled Substances Registration); HR592 (Pharmacy Provider Status); HR69 (ASP Prompt Pay Exclusion); HR793 (Any Willing Pharmacy); HR804 (Access to Medicare Data); HR818 (PRIME Act); HR971 (OPEN Act); HR1021 (PIMA); HR1353 (New Therapeutic Entities); HR1735 (NDAA); HR2175 (FEHBP Transparency); HR2298 (Medicare Rx Abuse Prevention); S31 (Direct Negotiation); S314 (Pharmacy Provider Status); S1083 (Medicare Rebates); S1190 (Any Willing Pharmacy); S1364 (Medicaid Generic Rebates); S1376 (NDAA); S1431(Rx Abuse Prevention & Treatment).
Client expense: Not reported · Firm income: Not reported
2015 · second_quarter · Taxation/Internal Revenue Code
Legislative and regulatory issues that affect the prescription drug benefit or prescription drug affordability, including: HR244 (MAC Pricing); HR471 (Controlled Substances Registration); HR592 (Pharmacy Provider Status); HR69 (ASP Prompt Pay Exclusion); HR793 (Any Willing Pharmacy); HR804 (Access to Medicare Data); HR818 (PRIME Act); HR971 (OPEN Act); HR1021 (PIMA); HR1353 (New Therapeutic Entities); HR1735 (NDAA); HR2175 (FEHBP Transparency); HR2298 (Medicare Rx Abuse Prevention); S31 (Direct Negotiation); S314 (Pharmacy Provider Status); S1083 (Medicare Rebates); S1190 (Any Willing Pharmacy); S1364 (Medicaid Generic Rebates); S1376 (NDAA); S1431(Rx Abuse Prevention & Treatment).
Client expense: Not reported · Firm income: Not reported
2015 · second_quarter · Medicare/Medicaid
Medicare; Medicaid; Pharmacy Payments; Average Manufacturer Pricing; Prescription Drug Reimburesement; Direct Negotiation; Medicare Drug Rebate; Medicare Part D Coverage; and HR 804, Expanding the Availability of Medicare Data Act
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · first_quarter · Pharmacy
Issues related to prescription drug abuse, pharmacist provider status, drug pricing and drug supply chain safety. HR 1600 :A bill to amend title XXVII of the Public Health Service Act to limit co-payment, coinsurance, or other cost-sharing requirements applicable to prescription drugs in a specialty drug tier to the dollar amount (or its equivalent) of such requirements applicable to prescription drugs in a non-preferred brand drug tier, and for other purposes. HR 804 - Expanding the Availability of Medicare Data Act HR 592 - Pharmacy and Medically Underserved Areas Enhancement Act S 314 - Pharmacy and Medically Underserved Areas Enhancement Act HR 244 - MAC Transparency Act H.R.1021 - Protecting the Integrity of Medicare Act of 2015 S.776 - Medication Therapy Management Empowerment Act of 2015 H.R.471 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015 S.483 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015
Client expense: $4,070,000 · Firm income: Not reported
2015 · first_quarter · Medicare/Medicaid
Medicare; Medicaid; Pharmacy Payments; Average Manufacturer Pricing; Prescription Drug Reimburesement; Direct Negotiation; Medicare Drug Rebate; Medicare Part D Coverage; and HR 804, Expanding the Availability of Medicare Data Act
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
| Democratic |
| WI |
| Mark Pocan | Democratic | WI |
| Reid J. Ribble | Republican | WI |
| Ron Kind | Democratic | WI |
| Sean P. Duffy | Republican | WI |
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), General Services Administration (GSA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE
Client expense: $643,584 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), General Services Administration (GSA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE
Client expense: $632,600 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), General Services Administration (GSA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE
Client expense: $632,600 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), General Services Administration (GSA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), General Services Administration (GSA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), General Services Administration (GSA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), General Services Administration (GSA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), General Services Administration (GSA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), General Services Administration (GSA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), General Services Administration (GSA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), General Services Administration (GSA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), General Services Administration (GSA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), General Services Administration (GSA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), General Services Administration (GSA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), General Services Administration (GSA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), General Services Administration (GSA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), General Services Administration (GSA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE